2.4.0.84050 - Disclosure - Goodwill (Details)truefalsefalse1false USDfalsefalse$D2013Q2http://www.sec.gov/CIK0000946840duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$D2012Q2http://www.sec.gov/CIK0000946840duration2012-04-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$D2013Q2YTDhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$D2012Q2YTDhttp://www.sec.gov/CIK0000946840duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$D2012Q4_6M_LevPharmaceuticalsIncMemberhttp://www.sec.gov/CIK0000946840duration2012-07-01T00:00:002012-12-31T00:00:00falsefalseLev Pharmaceuticals, Incus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_LevPharmaceuticalsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$D2012Q2_LevPharmaceuticalsIncMember_CinryzeMemberhttp://www.sec.gov/CIK0000946840duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseLev Pharmaceuticals, Incus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_LevPharmaceuticalsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCinryzeus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_CinryzeMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$I2008Q4_M1021_LevPharmaceuticalsIncMember_CinryzeMemberhttp://www.sec.gov/CIK0000946840instant2008-10-21T00:00:000001-01-01T00:00:00falsefalseLev Pharmaceuticals, Incus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_LevPharmaceuticalsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCinryzeus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_CinryzeMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDPerShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$D2013Q2YTD_LevPharmaceuticalsIncMember_CinryzeMember_MinimumMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseLev Pharmaceuticals, Incus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_LevPharmaceuticalsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCinryzeus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_CinryzeMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseMinimumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$D2012Q2_45M_LevPharmaceuticalsIncMember_CinryzeMember_MinimumMemberhttp://www.sec.gov/CIK0000946840duration2008-10-01T00:00:002012-06-30T00:00:00falsefalseLev Pharmaceuticals, Incus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_LevPharmaceuticalsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCinryzeus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_CinryzeMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseMinimumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$D2012Q3_DuoCortPharmaAbMemberhttp://www.sec.gov/CIK0000946840duration2012-07-01T00:00:002012-09-30T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false SEKtruefalseD2012Q3_DuoCortPharmaAbMemberhttp://www.sec.gov/CIK0000946840duration2012-07-01T00:00:002012-09-30T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberSEKStandardhttp://www.xbrl.org/2003/iso4217SEKiso42170SEKSEK12false truefalseI2011Q4_M1130_DuoCortPharmaAbMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli013false USDtruefalse$I2011Q4_M1115_DuoCortPharmaAbMemberhttp://www.sec.gov/CIK0000946840instant2011-11-15T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14false USDtruefalse$I2010Q2_M0531_AuralisLimitedMemberhttp://www.sec.gov/CIK0000946840instant2010-05-31T00:00:000001-01-01T00:00:00falsefalseAuralis Limitedus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_AuralisLimitedMemberus-gaap_BusinessAcquisitionAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_GoodwillLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Goodwill disclosures2false 4vphm_BusinessAcquisitionContingentConsiderationPotentialPaymentPerShareValuevphm_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse0.500.50USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalRepresents the per share value of contingent consideration pertaining to a business acquisition.No definition available.false3Contingent consideration, potential payment per share value3false 4vphm_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsvphm_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse8750000087500000USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of potential cash payments that could result from the contingent consideration arrangement.No definition available.false2Contingent consideration, potential cash payment4false 4vphm_CumulativeSalesThresholdNeededToTriggerContingentPaymentvphm_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse600000000600000000falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCumulative sales milestone threshold needed to trigger contingent payment.No definition available.false2Sales milestone threshold needed to trigger contingent payment5false 4us-gaap_SalesRevenueGoodsNetus-gaap_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:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Actual net product sales6false 4vphm_BusinessAcquisitionContingentConsiderationCashPaymentvphm_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse9230000092300000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the amount of cash payment for contingent acquisition.No definition available.false2Contingent consideration cash payment7false 4us-gaap_GoodwillPeriodIncreaseDecreaseus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse8630000086300000falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryChange in the carrying value of goodwill. The change could be the result of new goodwill acquired, goodwill impairment, if any, goodwill written off related to the sale of a business or other adjustments to goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph e -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 72 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Addition to goodwill8false 4us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillAmountus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse73000007300000falsefalsefalse14truefalsefalse59000005900000falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 52 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 53 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Recognized goodwill on acquisition9false 4us-gaap_GoodwillSubsequentRecognitionOfDeferredTaxAssetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse35000003500000USD$falsetruefalse11truefalsefalse2280000022800000SEKfalsetruefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of adjustments to goodwill resulting from the subsequent recognition of deferred tax assets during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 false2Adjustments to goodwill resulting from recognition of deferred tax assets10false 4us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquiredus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12truetruefalse1.001.00falsefalsefalse13falsetruefalse00falsefalsefalse14truetruefalse1.001.00falsefalsefalsenum:percentItemTypepurePercentage of voting equity interests acquired in the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 68 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Ownership interest (as a percent)falseGoodwill (Details)NoRoundingUnKnownNoRoundingUnKnowntruefalsetrueSheethttp://www.viropharma.com/role/DisclosureGoodwillDetails1410